CEL-SCI Co. (NYSEAMERICAN:CVM)’s stock price rose 6.4% during trading on Monday . The stock traded as high as $8.78 and last traded at $8.67, approximately 754,414 shares traded hands during trading. An increase of 6% from the average daily volume of 714,046 shares. The stock had previously closed at $8.15.
CEL-SCI (NYSEAMERICAN:CVM) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.27). The company had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.10 million.
A number of institutional investors have recently made changes to their positions in CVM. Thoroughbred Financial Services LLC lifted its stake in shares of CEL-SCI by 21.1% in the 1st quarter. Thoroughbred Financial Services LLC now owns 13,921 shares of the company’s stock worth $49,000 after purchasing an additional 2,428 shares during the period. Morgan Stanley increased its holdings in CEL-SCI by 12.0% in the 2nd quarter. Morgan Stanley now owns 27,255 shares of the company’s stock worth $228,000 after acquiring an additional 2,916 shares in the last quarter. Captrust Financial Advisors purchased a new stake in CEL-SCI in the 2nd quarter worth approximately $25,000. Steward Partners Investment Advisory LLC purchased a new stake in CEL-SCI in the 2nd quarter worth approximately $25,000. Finally, Endurance Wealth Management Inc. purchased a new stake in CEL-SCI in the 2nd quarter worth approximately $29,000.
CEL-SCI Company Profile (NYSEAMERICAN:CVM)
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.
Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.